Table 1 Correlation between the clinicopathologic characteristics and membranous, cytoplasmic and nuclear expression of β-catenin in 316 NSCLC patients

Variables

Cases

Low(102)

High(207)

p ^a

Low(176)

High(133)

p ^a

Low(170)

High(139)

p ^a

Gender

Male

134

42(31.3)

92(68.7)

0.586

74(55.2)

60(44.8)

0.590

73(54.5)

61(45.5)

0.868

Female

175

60(34.3)

115(65.7)

102(58.3)

73(41.7)

97(55.4)

78(44.6)

Age (years)^b

<52

149

59(39.6)

90(60.4)

0.017

85(57.0)

64(43.0)

0.976

77(51.7)

72(48.3)

0.255

≥52

160

43(26.9)

117(73.1)

91(56.9)

69(43.1)

93(58.1)

67(41.9)

Histologic subtype

Squamous carcinoma

142

47(33.1)

95(66.9)

0.976

87(61.3)

55(38.7)

0.158

85(59.9)

57(40.1)

0.115

Adenocarcinoma

167

55(32.9)

119(67.1)

89(53.3)

78(46.7)

85(50.9)

82(49.1)

Histologicalgrade

Grade 1

126

34(27.0)

92(73.0)

0.032

75(59.5)

51(40.5)

0.644

83(65.9)

43(34.1)

0.001

Grade 2

112

36(32.1)

76(67.9)

60(53.6)

52(46.4)

59(52.7)

53(47.3)

Grade 3

71

32(45.1)

39(54.9)

41(57.7)

30(42.3)

28(39.4)

43(60.6)

T classification

T1

71

23(32.4)

48(67.6)

0.069

43(60.6)

28(39.4)

0.349

40(56.3)

31(43.7)

0.727

T2

58

23(39.7)

35(60.3)

37(63.8)

21(36.2)

32(55.2)

26(44.8)

T3

126

39(31.0)

87(69.0)

70(55.6)

56(44.4)

72(57.1)

54(42.9)

T4

54

17(31.5)

37(68.5)

26(48.1)

28(51.9)

26(48.1)

28(51.9)

Clinical stage

I

108

35(32.4)

73(67.6)

0.818

62(57.4)

46(42.6)

0.957

56(51.9)

52(48.1)

0.689

II

81

29(35.8)

52(64.2)

45(55.6)

36(44.4)

45(55.6)

36(44.4)

III

120

38(31.7)

82(68.3)

69(57.5)

51(42.5)

69(57.5)

51(42.5)